// App-Quantinova.ai

TPS5603 : ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

Researchers

Presenter

  • Susana N. Banerjee

Principal Investigators

  • Bradley J. Monk

  • Els Van Nieuwenhuysen

  • Kathleen N. Moore

  • Ana Oaknin

  • Michel Fabbro

  • Nicoletta Colombo

  • David M. O'Malley

  • Robert L. Coleman

  • Jonathan A. Pachter

  • Andrew G. Koustenis

  • Gloria Patrick

  • Lorna Leonard

  • Rachel N. Grisham

Medical Centers

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ

  • KU Leuven, Leuven, Belgium

  • Stephenson Cancer Center, Oklahoma City, OK

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • CRLC Val d'Aurelle, Montpellier, France

  • European Institute of Oncology, Milan, Italy

  • The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, OH

  • University of Texas MD Anderson Cancer Center, Missouri City, TX.

  • Verastem, Inc., Needham, MA

  • Verastem, Needham, MA.

  • The Institute of Cancer Research: Royal Cancer Hospital, United Kingdom

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Locations

  • United Kingdom

  • United States

  • Belgium

  • Spain

  • France

  • Italy

Companies

  • Verastem, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • Focal Adhesion Kinase

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • VS-6063

  • VS 6766

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

  • Open Label

  • Multinational

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT03875820

  • NCT04625270

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved